Today we’re launching Endpoints Signal — a new biopharma intelligence platform that gives Endpoints News subscribers a trusted read on where biopharma is headed, and why. Signal is powered by surveying the Endpoints readership — the largest, most influential group of biopharma pros in the world.
Signal's flagship product is the Biopharma Sentiment Index, a new landmark quarterly gauge of the mood across biopharma. Each quarter we’re asking a consistent set of questions about business conditions, financing, regulation, organizational health, and hiring, that all roll up into one headline number that tracks sentiment over time. The inaugural report finds sentiment still bleak after four years of punishment — but showing surprising pockets of improvement.
Signal is led by Tom Randall, who comes to Endpoints after nearly two decades at Bloomberg. His award-winning work on the future of transportation and energy is known for combining quantitative rigor and great storytelling. Tom brings his talents back to the biopharma beat, where he began his career. Endpoints subscribers will have exclusive access to his team’s insights.
From big pharma CEOs to biotech entrepreneurs, bench scientists to the salesforce — our mission at Endpoints is to keep subscribers in the know. But there’s also so much to learn from them. Signal is another step toward a two-way conversation with readers. Combining structured reader surveys with custom market data and sharp editorial analysis is Signal’s recipe for meaningful insights you won’t find elsewhere.
Endpoints Signal complements our journalism, building on nearly 10 years of important work by our reporters and editors, publishing a comprehensive set of trusted news reports every day covering everything that matters in the life sciences.
Readers will begin to see Signal components on the web and by email. As a life science professional, your take on our questions is valuable, as is your time. Participation is always optional, and response data is anonymized and aggregated.
Read more from Endpoints Signal:
Biopharma Sentiment Index | Q4 2025
Heavy AI users are taking over biopharma | Pulse Report
Explore the Endpoints Signal homepage
Interested in conducting your own research questions or custom analysis? We have a very limited number of opportunities available for select clients. Contact our sales team at signal@endpoints.news.
↧